Status:
COMPLETED
Effect of Oral Combined Berberine and Curcumin Pharmacological Therapy on IBS
Lead Sponsor:
Liaquat University of Medical & Health Sciences
Collaborating Sponsors:
University of Liege
Conditions:
Irritable Bowel Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Irritable bowel syndrome (IBS) is a prevalent, chronic functional gastrointestinal (GI) disorder, characterized by recurrent abdominal discomfort (pain) associated with altered bowel movements. IBS ha...
Detailed Description
Aim of the study: The present clinical study aimed to assess the synergestic therapeutic effect of a combined supplement of standardised extract of BBR and CUR (Enterophytol® PLUS, 200 mg BBR, 49 mg ...
Eligibility Criteria
Inclusion
- Self-completion of simplified form of the Rome IV IBS diagnostic criteria
- Had IBS symptoms that appeared before the age of 50
- Used Enterophytol® PLUS as complementary therapy as two tablets a day for 2-months
Exclusion
- Those with involuntary weight loss
- Family history of chronic inflammatory bowel disease, colorectal cancer, celiac disease, rectal discharge, nocturnal symptoms, fever, and abnormalities on clinical examination (abdominal mass, signs of anaemia).
Key Trial Info
Start Date :
August 25 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT06187298
Start Date
August 25 2020
End Date
December 15 2023
Last Update
January 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Liaquat University of Medical and Health Sciences
Jāmshoro, Pakistan